热门资讯> 正文
ARCA生物制药GAAP每股收益为-0.14美元
2024-04-26 05:17
- ARCA biopharma press release (NASDAQ:ABIO): Q1 GAAP EPS of -$0.14.
- Cash and cash equivalents were $35.9 million as of March 31, 2024, compared to $37.4 million as of December 31, 2023. ARCA believes that its current cash and cash equivalents, consisting primarily of money market funds, will be sufficient to fund its operations through the middle of 2025.
More on ARCA biopharma
- ARCA biopharma to merge with Oruka Therapeutics in all-stock transaction
- Financial information for ARCA biopharma
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
